Accelerating Parkinson's Disease drug development with federated learning approaches

Amit Khanna; Jamie Adams; Chrystalina Antoniades; Bastiaan R Bloem; Camille Carroll; Jesse Cedarbaum; Joshua Cosman; David T Dexter; Marissa F Dockendorf; Jeremy Edgerton; Laura Gaetano; Erkuden Goikoetxea; Derek Hill; Fay Horak; Elena S Izmailova; Tairmae Kangarloo; Dina Katabi; Catherine Kopil; Michael Lindemann; Jennifer Mammen; Kenneth Marek; Kevin McFarthing; Anat Mirelman; Martijn Muller; Gennaro Pagano; M Judith Peterschmitt; Jie Ren; Lynn Rochester; Sakshi Sardar; Andrew Siderowf; Tanya Simuni; Diane Stephenson; Christine Swanson-Fischer; John A Wagner; Graham B Jones

doi:10.1038/s41531-024-00837-5

Back

Accelerating Parkinson's Disease drug development with federated learning approaches

Journal article

Peer reviewed

Accelerating Parkinson's Disease drug development with federated learning approaches

Amit Khanna, Jamie Adams, Chrystalina Antoniades, Bastiaan R Bloem, Camille Carroll, Jesse Cedarbaum, Joshua Cosman, David T Dexter, Marissa F Dockendorf, Jeremy Edgerton, …

NPJ Parkinson's Disease, Vol.10(1), pp.225-9

11/21/2024

DOI: https://doi.org/10.1038/s41531-024-00837-5

PMID: 39567515

Abstract

Parkinson's Disease is a progressive neurodegenerative disorder afflicting almost 12 million people. Increased understanding of its complex and heterogenous disease pathology, etiology and symptom manifestations has resulted in the need to design, capture and interrogate substantial clinical datasets. Herein we advocate how advances in the deployment of artificial intelligence models for Federated Data Analysis and Federated Learning can help spearhead coordinated and sustainable approaches to address this grand challenge.

Files and links (1)

url

https://doi.org/10.1038/s41531-024-00837-5View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Accelerating Parkinson's Disease drug development with federated learning approaches
Creators: Amit Khanna - Neuroscience Development, Novartis AG, Basel, Switzerland
Jamie Adams - University of Rochester
Chrystalina Antoniades - University of Oxford
Bastiaan R Bloem - Radboud University Nijmegen
Camille Carroll - Newcastle University
Jesse Cedarbaum - Yale University
Joshua Cosman - AbbVie
David T Dexter - Parkinson's UK
Marissa F Dockendorf - MSD
Jeremy Edgerton - Biogen
Laura Gaetano - Novartis
Erkuden Goikoetxea - UCB Pharma
Derek Hill - Digital Health Cooperative Research Centre
Fay Horak - Oregon Health & Science University
Elena S Izmailova - Koneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA
Tairmae Kangarloo - Takeda
Dina Katabi - Massachusetts Institute of Technology
Catherine Kopil - Michael J. Fox Foundation
Michael Lindemann - Roche
Jennifer Mammen - University of Massachusetts Dartmouth
Kenneth Marek - Institute for Neurodegenerative Disorders
Kevin McFarthing - Parkinson's UK
Anat Mirelman - Tel Aviv University
Martijn Muller - Critical Path Institute
Gennaro Pagano - Roche
M Judith Peterschmitt - Research and Development, Sanofi, Cambridge, MA, USA
Jie Ren - MSD
Lynn Rochester - Newcastle University
Sakshi Sardar - Critical Path Institute
Andrew Siderowf - University of Pennsylvania
Tanya Simuni - Northwestern University
Diane Stephenson - Critical Path Institute
Christine Swanson-Fischer - National Institute of Neurological Disorders and Stroke
John A Wagner - Koneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA
Graham B Jones - Tris Pharma
Publication Details: NPJ Parkinson's Disease, Vol.10(1), pp.225-9
Language: English
Academic Unit: Department of Adult Nursing
Resource Type: Journal article
Identifiers: 9914414958001301